Ligand Right of Second Negotiation. 3.2.1 In the event that Retrophin desires to enter into a Business Opportunity, before entering into negotiations with any Third Party and after following the procedure set forth in Section 3.1 above, with respect to such License, Retrophin shall notify Ligand and provide Ligand with information necessary or useful to Ligand to evaluate the proposed License arrangement (“Evaluation Information”). The Parties shall negotiate in good faith the terms pursuant to which Ligand may obtain such Business Opportunity for a period of [***] days following the date of such notice (such period referred to as the “Ligand Negotiation Period”).
Appears in 4 contracts
Samples: Sublicense Agreement (Ligand Pharmaceuticals Inc), Sublicense Agreement (Ligand Pharmaceuticals Inc), Sublicense Agreement (Desert Gateway, Inc.)
